Tsumura & Co AI Stock Analysis
Want to see JP:4540 full AI Analyst Report?
Tsumura & Co (4540) AI Stock Analysis
Tsumura & Co
(TSE/TYO:4540)
The score is primarily supported by attractive valuation (low P/E and strong dividend yield) and solid reported profitability, but it is held back by weak cash generation (negative free cash flow and poor cash conversion) and only neutral technical signals.
Tsumura & Co (4540) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 1.73B
- Dividend Yield
- 4.12%
- Average Volume (3M)
- 508.05K
- Price to Earnings (P/E)
- 9.0
- Beta (1Y)
- 0.39
- Revenue Growth
- 13.32%
- EPS Growth
- 17.39%
- Country
- Japan
- Employees
- 4,923
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Tsumura & Co Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extr...
How the Company Makes Money
Tsumura makes money primarily by selling Kampo medicines and related products. Its largest revenue stream is domestic pharmaceutical sales of prescription Kampo formulations that are manufactured by Tsumura and distributed to medical institutions and...
Tsumura & Co Financial Statement Overview
Summary
Income statement strength (Score 82) shows solid profitability and positive revenue growth, and the balance sheet is generally stable (Score 74) with moderate leverage. However, cash flow is a major drag (Score 46) with negative free cash flow and weak cash conversion, which materially lowers overall financial quality.
Income Statement
82Very PositiveBalance Sheet
74PositiveCash Flow
46Neutral| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 189.50B | 181.09B | 192.62B | 150.84B | 140.04B | 129.55B |
| Gross Profit | 90.20B | 90.58B | 91.52B | 68.82B | 68.28B | 66.47B |
| EBITDA | 53.75B | 57.25B | 55.15B | 34.82B | 34.03B | 34.92B |
| Net Income | 29.01B | 32.43B | 28.12B | 16.71B | 16.48B | 18.84B |
Balance Sheet | ||||||
| Total Assets | 549.68B | 464.38B | 592.77B | 428.25B | 396.81B | 350.98B |
| Cash, Cash Equivalents and Short-Term Investments | 69.48B | 73.23B | 84.08B | 78.08B | 94.75B | 67.55B |
| Total Debt | 135.41B | 70.80B | 135.16B | 80.10B | 80.05B | 50.00B |
| Total Liabilities | 211.04B | 134.27B | 221.16B | 132.89B | 124.56B | 92.87B |
| Stockholders Equity | 305.33B | 300.53B | 321.73B | 270.80B | 252.05B | 239.77B |
Cash Flow | ||||||
| Free Cash Flow | -21.99B | 6.23B | -8.06B | -11.21B | 4.23B | 11.14B |
| Operating Cash Flow | 15.40B | 33.82B | 24.72B | 5.61B | 16.45B | 21.31B |
| Investing Cash Flow | -46.44B | -24.97B | -50.31B | -19.35B | -15.49B | -9.11B |
| Financing Cash Flow | 20.41B | -19.87B | 32.60B | -4.42B | 24.42B | -8.18B |
Tsumura & Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4540, the sentiment is Positive. The current price of 3838.00 is above the 20-day moving average (MA) of 3800.20, above the 50-day MA of 3751.66, and above the 200-day MA of 3744.14, indicating a bullish trend. The MACD of 27.75 indicates Negative momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 65.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4540.
Tsumura & Co Peers Comparison
Overall Rating
JP:451670.5Outperform- JP:454070Outperform
JP:453468Neutral
JP:452164.9Neutral
JP:292957Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4516 | 71Outperform | JPY 232.23B | 7.29 | ― | 3.66% | 12.23% | 3.35% |
| JP:4540 | 70Outperform | JPY 298.46B | 9.01 | 9.84% | 4.12% | 13.32% | 17.39% |
| JP:4534 | 68Neutral | JPY 111.10B | 10.96 | 7.68% | 2.51% | 15.85% | 60.55% |
| JP:4521 | 65Neutral | JPY 135.61B | 15.77 | 6.11% | 5.01% | 5.43% | 1167.63% |
| JP:2929 | 57Neutral | JPY 16.51B | 8.30 | ― | 3.88% | -3.12% | 406.78% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4540 | Tsumura & Co | 3838.00 | 80.45 | 2.14% | |
| JP:4521 | Kaken Pharmaceutical Co | 3790.00 | 346.24 | 10.05% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3285.00 | 180.48 | 5.81% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 566.00 | -211.24 | -27.18% | |
| JP:4516 | Nippon Shinyaku Co., Ltd. | 3392.00 | 132.33 | 4.06% |
Tsumura & Co Corporate Events
Tsumura Includes Yomeishu Seizo in Interim Consolidated Results
Tsumura & Co. develops and sells prescription Kampo formulations and healthcare products, including over-the-counter Kampo medicines, serving Japan’s traditional herbal medicine market.The company released supplementary materials for the second quart...
Tsumura Reports Strong First-Half Sales and Profit Growth
Tsumura & Co. reported higher results for the six months ended September 30, 2026, with net sales rising 15.1% year over year to ¥103.4 billion. Operating profit increased 10.1% to ¥18.8 billion, ordinary profit climbed 23.7% to ¥20.3 billion, and pr...
Tsumura Lifts Earnings Forecast on Yomeishu Deal Despite China Weakness
Tsumura & Co. has revised its consolidated earnings forecasts for the first half and full year to March 31, 2027, citing stronger interim profits and the consolidation of Yomeishu Seizo. The company now expects higher net sales and profit attributabl...
Tsumura Takes Yomeishu Seizo Private to Boost OTC and Preventive Healthcare
Tsumura & Co. has completed the acquisition of all shares of Yomeishu Seizo Co., Ltd. from Yuzawa Co., Ltd., paying 6.8 billion yen to take full ownership and integrate the long-established maker of Yomeishu and related products. The deal, effective...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026